H1 Report 2018

MOR106 is an antibody designed to target IL-17C, which potentially plays an important role in skin disorders like AtD.

Financial highlights

Group revenues

101.9 million

Read more

Cash position

1066.8 million

Read more

Letter from the management

We have had an incredibly productive first half year 2018.
Read more